Loading institutional data...
Loading institutional data...
Held by 211 of 5,944 reporting institutions (92th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Modest payoff on reinvested capital. Current ROIC on all capital: -7%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~340.9% on $9M of debt.
Cash of $226M fully covers short-term debt of $9M.
Mostly short-term debt (balance-sheet current vs non-current split). A year-by-year maturity schedule wasn't disclosed for this issuer.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-09-17
Nothing notable to watch.
Is the profit real, and how strong is the balance sheet?
FY2026 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2020 | FY2021 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 76.3 | 88.3 | 76.0 | 81.4 | 76.6 | 71.7 | 70.7 | 71.6 |
| Gross Profit | 23.7 | 11.7 | 24.0 | 18.6 | 23.4 | 28.3 | 29.3 | 28.4 |
| R&D | 0.5 | 2.1 | 0.2 | 0.2 | 0.1 | 0.1 | 0.0 | 0.0 |
| SG&A | 23.1 | 40.8 | 21.7 | 25.9 | 26.3 | 21.2 | 20.4 | 22.2 |
| Operating Income | -25.7 | -95.6 | -25.8 | -97.1 | -218.4 | -22.1 | -277.9 | -6.9 |
| Income Tax | -2.1 | -2.7 | -1.7 | -1.0 | -1.1 | -3.4 | -14.7 | 1.9 |
| Net Income | -25.3 | -128.8 | -71.6 | -75.9 | -231.6 | -31.1 | -266.3 | -13.3 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on TLRY: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2026
Each value shows its share of revenue below it (common-size).
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2021 | FY2020 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $915.5M 100.0% | $821.3M 100.0% | $788.9M 100.0% | $627.1M 100.0% | $628.4M 100.0% | $513.1M 100.0% | $210.5M 100.0% | $405.3M 100.0% | $167.0M 100.0% | $179.3M 100.0% |
| Cost of Revenue | $655.0M 71.6% | $580.7M 70.7% | $565.6M 71.7% | $480.2M 76.6% | $511.6M 81.4% | $389.9M 76.0% | $185.8M 88.3% | $309.3M 76.3% | $190.5M 114.1% | $135.8M 75.7% |
| Gross Profit | $260.4M 28.4% | $240.6M 29.3% | $223.4M 28.3% | $147.0M 23.4% | $116.8M 18.6% | $123.2M 24.0% | $24.7M 11.7% | $96.1M 23.7% | -$23.5M -14.1% | $43.5M 24.3% |
| Research & Development | $361K 0.0% | $284K 0.0% | $635K 0.1% | $682K 0.1% | $1.5M 0.2% | $830K 0.2% | $4.4M 2.1% | $1.9M 0.5% | $9.2M 5.5% | $1.1M 0.6% |
| Selling, General & Admin | $203.6M 22.2% | $167.3M 20.4% | $167.4M 21.2% | $165.2M 26.3% | $162.8M 25.9% | $111.6M 21.7% | $85.9M 40.8% | $93.8M 23.1% | $110.9M 66.4% | $75.8M 42.3% |
| Total Operating Expenses | $323.5M 35.3% | $2.52B 307.2% | $398.1M 50.5% | $1.52B 241.8% | $727.2M 115.7% | $255.4M 49.8% | — | $200.1M 49.4% | — | $182.4M 101.8% |
| Operating Income | -$63.0M -6.9% | -$2.28B -277.9% | -$174.7M -22.1% | -$1.37B -218.4% | -$610.4M -97.1% | -$132.2M -25.8% | -$201.1M -95.6% | -$104.0M -25.7% | -$304.1M -182.1% | -$138.9M -77.5% |
| Interest Expense | $29.9M 3.3% | $41.3M 5.0% | $49.3M 6.2% | $46.6M 7.4% | $39.7M 6.3% | $30.9M 6.0% | — | $25.6M 6.3% | — | — |
| Interest & Investment Income | $6.2M 0.7% | $11.4M 1.4% | $12.8M 1.6% | $33.0M 5.3% | $11.7M 1.9% | $2.9M 0.6% | $798K 0.4% | $6.3M 1.5% | $149K 0.1% | — |
| Other Income (Expense), net | -$1.4M -0.1% | $10.3M 1.3% | -$37.8M -4.8% | -$66.9M -10.7% | $197.7M 31.5% | -$184.8M -36.0% | -$10.3M -4.9% | $14.2M 3.5% | $2.5M 1.5% | $95.5M 53.3% |
| Pretax Income | -$88.1M -9.6% | -$2.30B -280.3% | -$249.0M -31.6% | -$1.45B -231.2% | -$440.7M -70.1% | -$345.0M -67.2% | -$276.7M -131.4% | -$109.2M -26.9% | -$329.6M -197.4% | -$38.1M -21.3% |
| Income Tax Expense | $17.1M 1.9% | -$121.0M -14.7% | -$26.6M -3.4% | -$7.2M -1.1% | -$6.5M -1.0% | -$9.0M -1.7% | -$5.6M -2.7% | -$8.4M -2.1% | -$8.4M -5.1% | -$2.0M -1.1% |
| Net Income | -$121.4M -13.3% | -$2.19B -266.3% | -$245.0M -31.1% | -$1.45B -231.6% | -$476.8M -75.9% | -$367.4M -71.6% | -$271.1M -128.8% | -$102.5M -25.3% | -$321.2M -192.3% | -$25.0M -14.0% |
| Per Share | ||||||||||
| EPS (Basic) | $-1.09 | $-24.56 | $-3.30 | $-2.35 | $-0.99 | $-1.36 | — | $-0.47 | — | $-0.18 |
| EPS (Diluted) | $-1.09 | $-24.56 | $-3.30 | $-2.35 | $-0.99 | $-1.36 | — | $-0.47 | — | $-0.18 |
| Weighted Avg Shares (Basic) | 111.8M | 89.0M | 74.3M | 618.0M | 481.2M | 269.5M | — | 216.2M | — | 203.5M |
| Weighted Avg Shares (Diluted) | 111.8M | 89.0M | 74.3M | 618.0M | 481.2M | 269.5M | — | 216.2M | — | 203.5M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| TLRY | $519M | — | — | 0.6× | 11.5% | 28.4% | -13.3% | -7.5% | -7.5% | — | 211 |
Peers = companies sharing TLRY's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.